Erasca Inc. (NASDAQ: ERAS) announced preliminary Phase 1 data for its experimental cancer drug ERAS-0015, showing response rates in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE